Species-specific action of (Pro3)GIP - A full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors

British Journal of Pharmacology

Volumn 173, Issue 1, 2016, Pages 27-38

  Sparre Ulrich, A H ^a   Hansen, L S ^a   Svendsen, B ^b   Christensen, M ^c   Knop, F K ^c   Hartmann, B ^b   Holst, J J ^b   Rosenkilde, M M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NNF Center for Basic Metabolic Research   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

(PRO3)GASTRIC INHIBITORY POLYPEPTIDE; CYCLIC AMP; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR; HORMONE RECEPTOR; UNCLASSIFIED DRUG; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GLUCAGON; GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE, PRO(3)-; INSULIN; RADIOACTIVE IODINE; SOMATOSTATIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOACCUMULATION; COMPETITIVE BINDING ASSAY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN VERSUS ANIMAL COMPARISON; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN FUNCTION; RAT; SPECIES DIFFERENCE; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; CHLOROCEBUS AETHIOPS; COMPARATIVE STUDY; COS CELL LINE; DOSE RESPONSE; DRUG EFFECTS; HUMAN; METABOLISM; PANCREAS; PARTIAL AGONISM; RADIOASSAY;

ANIMALS; BINDING, COMPETITIVE; CERCOPITHECUS AETHIOPS; COS CELLS; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PARTIAL AGONISM; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; HUMANS; INSULIN; IODINE RADIOISOTOPES; MALE; MICE; PANCREAS; RADIOLIGAND ASSAY; RATS; RECEPTORS, GASTROINTESTINAL HORMONE; SOMATOSTATIN; SPECIES SPECIFICITY;

EID: 84952636828     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13323     Document Type: Article

References (61)

1. Ahlqvist E, Osmark P, Kuulasmaa T, Pilgaard K, Omar B, Brøns C, et al., (2013). Link between GIP and osteopontin in adipose tissue and insulin resistance. Diabetes 62: 2088-2094.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., (2013). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
3. Allen SJ, Crown SE, Handel TM, (2007). Chemokine:receptor structure, interactions, and antagonism. Annu Rev Immunol 25: 787-820.
4. Al-Sabah S, Al-Fulaij M, Ahmed HA, (2014). Selectivity of peptide ligands for the human incretin receptors expressed in HEK-293 cells. Eur J Pharmacol 741: 311-315.
5. Asmar M, Simonsen L, Madsbad S, Stallknecht B, Holst JJ, Bülow J, (2010). Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans. Diabetes 59: 2160-2163.
6. Baggio LL, Drucker DJ, (2007). Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157.
7. Baldissera FGA, Munoz-Perez MA, Holst JJ, (1983). Somatostatin 1-28 circulates in human plasma. Regul Pept 6: 63-69.
8. Brand CL, Jorgensen PN, Knigge U, Warberg J, Svendsen I, Kristensen JS, et al., (1995). Role of glucagon in maintenance of euglycemia in fed and fasted rats. Am J Physiol 269: E469-E477.
9. Brøns C, Jensen CB, Storgaard H, Hiscock NJ, White A, Appel JS, et al., (2009). Impact of short-term high-fat feeding on glucose and insulin metabolism in young healthy men. J Physiol 587: 2387-2397.
10. Calanna S, Christensen M, Holst JJ, Laferrère B, Gluud LL, Vilsbøll T, et al., (2013). Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies. Diabetes Care 36: 3346-3352.
11. Canal CE, Cordova-Sintjago T, Liu Y, Kim MS, Morgan D, Booth RG, (2013). Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligands. J Pharmacol Exp Therapeut 347: 705-716.
12. Castro M, Nikolaev VO, Palm D, Lohse MJ, Vilardaga J-P, (2005). Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism. Proc Natl Acad Sci U S A 102: 16084-16089.
13. Christensen M, Vedtofte L, Holst JJ, Vilsboell T, Knop FK, (2011). Glucose-Dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 60: 3103-3109.
14. De Toro-Martin J, Fernandez-Millan E, Lizarraga-Mollinedo E, Lopez-Oliva E, Serradas P, Escriva F, et al., (2014). Predominant role of GIP in the development of a metabolic syndrome-like phenotype in female Wistar rats submitted to forced catch-up growth. Endocrinology 155: 3769-3780.
15. Deacon CF, Plamboeck A, Rosenkilde MM, deHeer J, Holst JJ, (2006). GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations. Am J Physiol Endocrinol Metabol 291: E468-E475.
16. Deblasi A, O'reilly K, Motulsky HJ, (1989). Calculating receptor number from binding experiments using same compound as radioligand and competitor. Trends Pharmacol Sci 10: 227-229.
17. Deschamps I, Heptner W, Desjeux JF, Baltakse V, Machinot S, Lestradet H, (1980). Effects of diet on insulin and gastric inhibitory polypeptide levels in obese children. Pediatr Res 14: 300-303.
18. Ebert R, Illmer K, Creutzfeldt W, (1979). Release of gastric inhibitory polypeptide (GIP) by intraduodenal acidification in rats and humans and abolishment of the incretin effect of acid by GIP-antiserum in rats. Gastroenterology 76: 515-523.
19. Fulurija A, Lutz TA, Sladko K, Osto M, Wielinga PY, Bachmann MF, et al., (2008). Vaccination against GIP for the treatment of obesity. PLoS One 3: e3163.
20. Gardella TJ, Jüppner H, (2001). Molecular properties of the PTH/PTHrP receptor. Trends Endocrinol Metabol 12: 210-217.
21. Gault Victor A, Hunter K, Irwin N, Greer B, Green Brian D, Harriott P, et al., (2007). Characterisation and glucoregulatory actions of a novel acylated form of the (Pro3)GIP receptor antagonist in type 2 diabetes. Biol Chem 388: 173.
22. Gault VA, O'harte FPM, Harriott P, Flatt PR, (2002). Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem Biophys Res Commun 290: 1420-1426.
23. Gault VA, O'harte FPM, Harriott P, Mooney MH, Green BD, Flatt PR, (2003). Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia 46: 222-230.
24. Gault VA, Mcclean PL, Cassidy RS, Irwin N, Flatt PR, (2007). Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 50: 1752-1762.
25. Gelling RW, Coy DH, Pederson RA, Wheeler MB, Hinke S, Kwan T, et al., (1997). GIP(6-30amide) contains the high affinity binding region of GIP and is a potent inhibitor of GIP1-42 action in vitro. Regul Pept 69: 151-154.
26. Gourlet P, Vilardaga J-P, De Neef P, Waelbroeck M, Vandermeers A, Robberecht P, (1996). The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors. Peptides 17: 825-829.
27. Gutniak M, Orskov C, Holst JJ, Ahrén B, Efendic S, (1992). Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. New Engl J Med Massachusetts Medical Society 326: 1316-1322.
28. de Heer J, Rasmussen C, Coy DH, Holst JJ, (2008). Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51: 2263-2270.
29. Hinke SA, Manhart S, Pamir N, Demuth HU, Gelling W, Pederson RA, et al., (2001). Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP). Biochim Biophys Acta Protein Struct Mol Enzymol 1547: 143-155.
30. Hjorth SA, Schwartz TW, (1996). Glucagon and GLP-1 receptors: lessons from chimeric ligands and receptors. Acta Physiol Scand 157: 343-345.
31. Holst JJ, (2004). On the Physiology of GIP and GLP-1. Horm Metab Res 36: 747-754.
32. Irwin N, Green BD, Parker JC, Gault VA, O'harte FPM, Flatt PR, (2006). Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16). Regul Pept 135: 45-53.
33. Irwin N, Mcclean PL, O'harte FPM, Gault VA, Harriott P, Flatt PR, (2007). Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia 50: 1532-1540.
34. Irwin N, Mcclean PL, Patterson S, Hunter K, Flatt PR, (2009). Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes. Biol Chem 390: 75.
35. Jørgensen NB, Dirksen C, Bojsen-Møller KN, Jacobsen SH, Worm D, Hansen DL, et al., (2013). Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 62: 3044-3052.
36. Kerr BD, Flatt AJS, Flatt PR, Gault VA, (2011). Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptide. Biochem Biophys Res Commun 404: 870-876.
37. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
38. Kissow H, Hartmann B, Holst JJ, Viby NE, Hansen LRS, Rosenkilde MM, et al., (2012). Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regul Pept 179: 91-100.
39. Klos A, Wende E, Wareham KJ, Monk PN, (2013). International Union of Basic and Clinical Pharmacology. LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors. Pharmacol Rev 65: 500-543.
40. Knudsen LB, Hastrup S, Underwood CR, Wulff BS, Fleckner J, (2012). Functional importance of GLP-1 receptor species and expression levels in cell lines. Regul Pept 175: 21-29.
41. Kreymann B, Ghatei MA, Williams G, Bloom SR, (1987). Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 330: 1300-1304.
42. Lazareno S, Birdsall NJ, (1993). Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations. Br J Pharmacol 109: 1110-1119.
43. Malde AK, Srivastava SS, Coutinho EC, (2007). Understanding interactions of gastric inhibitory polypeptide (GIP) with its G-protein coupled receptor through NMR and molecular modeling. J Pept Sci 13: 287-300.
44. Mcclean PLI, (2007). GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metabol 293: E1746-E1755.
45. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
46. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, et al., (1999). Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci 96: 14843-14847.
47. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, et al., (2002). Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8: 738-742.
48. Nakamura T, Tanimoto H, Mizuno Y, Tsubamoto Y, Noda H, (2012). Biological and functional characteristics of a novel low-molecular weight antagonist of glucose-dependent insulinotropic polypeptide receptor, SKL-14959, in vitro and in vivo. Diabetes Obes Metabol 14: 511-517.
49. Nasteska D, Harada N, Suzuki K, Yamane S, Hamasaki A, Joo E, et al., (2014). Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions. Diabetes 63: 2332-2343.
50. Orskov C, Jeppesen J, Madsbad S, Holst JJ, (1991). Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87: 415-423.
51. Parthier C, Kleinschmidt M, Neumann P, Rudolph R, Manhart S, Schlenzig D, et al., (2007). Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor. Proc Natl Acad Sci 104: 13942-13947.
52. Pathak V, Gault VA, Flatt PR, Irwin N, (2015). Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice. Mol Cell Endocrinol 401: 120-129.
53. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al., (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
54. Raufman JP, Singh L, Eng J, (1991). Exendin-3, a novel peptide from Heloderma horridum venom, interacts with vasoactive intestinal peptide receptors and a newly described receptor on dispersed acini from guinea pig pancreas. Description of exendin-3(9-39) amide, a specific exendin receptor antagonist. J Biol Chem 266: 2897-2902.
55. Ravn P, Madhurantakam C, Kunze S, Matthews E, Priest C, O'brien S, et al., (2013). Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor. J Biol Chem 288: 19760-19772.
56. Scott JS, Brocklehurst KJ, Brown HS, Clarke DS, Coe H, Groombridge SD, et al., (2013). Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human. Bioorg Med Chem Lett 23: 3175-3179.
57. Thiele S, Rosenkilde M, (2014). Interaction of chemokines with their receptors-from initial chemokine binding to receptor activating steps. Curr Med Chem 21: 3594-3614.
58. Tikhele SH, Pissurlenkar RRS, Srivastava S, Saran A, Coutinho EC, (2010). Mapping interactions of gastric inhibitory polypeptide with GIPR N-terminus using NMR and molecular dynamics simulations. J Pept Sci 16: 383-391.
59. Tseng CC, Kieffer TJ, Jarboe LA, Usdin TB, Wolfe MM, (1996). Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J Clin Invest 98: 2440-2445.
60. Venneti KC, Malthouse JP, O'harte FPM, Hewage CM, (2011). Conformational, receptor interaction and alanine scan studies of glucose-dependent insulinotropic polypeptide. Biochim Biophys Acta Protein Proteonomics 1814: 882-888.
61. Vilardaga J-P, Romero G, Friedman P, Gardella T, (2011). Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm. Cell Mol Life Sci 68: 1-13.